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ABSTRACT 
Objective: The objective of present investigation was to develop rivastigmine tartrate transdermal film employing factorial design. 
Methods: The formulations were designed by Design-Expert software-version10. A series of films were prepared by solvent casting method using 
polymers, plasticizer, permeation enhancer and other solvents. Transdermal films were evaluated for flatness, drug content, tensile strength, in vitro 
drug release and ex vivo skin permeation study. 
Results: The flatness was found 100% (percentage) for all film formulations. The drug content of transdermal film was found in the range of 
96.51±0.2 to 98.81±0.3%. The tensile strength of transdermal film was found in the range of 6.28±0.06 to 11.56±0.03 N/mm2 (newton/millimeter2) 
and in vitro drug release at 24th h (hour) was found in the range of 86.24±0.25 to 96.1±0.48% for various formulations and ex vivo skin permeation 
study results at 24th h was found in the range of 85.83±0.74 to 97.36±0.93%. 
Conclusion: These results support the feasibility of developing transdermal film of rivastigmine tartrate for human applications. Thus, transdermal 
delivery of rivastigmine tartrate film is a safe, painless and cost effective drug delivery system for Alzheimer’s patients. 
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Alzheimer’s disease (AD) is the most common form of dementia 
among older people, accounting for 50-70% of the cases [1, 2]. 
Dementia is a broader term than AD and refers to any acquired brain 
syndrome resulting in deteriorating mental functions, severe enough 
to impair the individual’s normal daily life situation [3]. An insidious, 
progressive, neurodegenerative disease, the pathogenic process in 
AD starts probably decades before the clinical onset of symptoms. 
In the past thirty years, there has been an explosion in the creation 
and discovery of new medicinal agents. Innovations in drug delivery 
have not only enabled successful implementation of these 
pharmaceuticals, but also promoted the developments of new 
medical treatments with existing drugs. The creation of a 
transdermal drug delivery system (TDDS) has been one of the most 
important innovations. Transdermal products for cardiovascular 
disease, Parkinson’s disease, Alzheimer’s disease, depression, 
anxiety, skin cancer, and post-menopausal bone loss are at various 
stages of formulation and development [4-7]. 
For decades, a variety of pharmaceutical dosage forms like capsules, 
tablets, suppositories, liquids, ointments, creams, aerosols, 
injections, etc. have been used as drug delivery systems to treat 
chronic and acute diseases. Colloidal drug delivery systems namely 
micelles, oil-in-water emulsions, micro particles, nanoparticles and 
liposomes have been employed for controlled drug delivery. 
Nanoparticles are solid colloidal particles in which the active 
ingredients are dissolved, entrapped and to which the active 
principle is attached or adsorbed. A nanoparticle offers so many 
benifits in drug delivery because of their small particle size and large 
surface area. Nanoparticles can be used to target the delivery of 
drugs, to prolong its effect, to enhance bioavailability, to solubilize it 
for intravascular delivery and to get better its stability against 
enzymatic degradation [8, 9]. Based on the type of the inactive 
ingredient used, there are four classes of nanoparticles: Lipid based 
nanoparticles [10], polymeric nanoparticles [11], metal based 
nanoparticles [12] and biological nanoparticles [13]. 
In the present study solid lipid nanoparticles of rivastigmine tartrate 
were incorporated into transdermal films and evaluated. 
MATERIALS AND METHODS 
Materials 
Rivastigmine Tartrate was obtained as a gift sample from jubilant 
life sciences Ltd, Nanjangud, Mysuru, India. Hydroxy propyl methyl 
cellulose was procured from loba chemie, Mumbai, India. eudragit rs 
100 and eudragit l 100 was purchased from Degussa India Pvt Ltd, 
Mumbai, India. Glycerol was obtained from merck specialities pvt 
ltd, Mumbai, India. All other solvents, reagents and chemicals used 
were of analytical grade. 
Experimental methods 
Preparation of solid lipid nanoparticles (SLN) 
SLN of rivastigmine tartrate was prepared by modified solvent 
emulsification diffusion method. The drug was dissolved in distilled 
water (internal phase). Required quantity of surfactant (poloxamer 
188) and required quantity of lipid (stearic acid) were dissolved in 10 
ml (milliliter) of distilled water and heated for 10 min (minutes) and 
propylene glycol was added to stearic acid solution (external phase). 
External phase was added to internal phase solution and 10 ml of 70 
% aqueous ethanol (co-solvent) was added to above solution and the 
mixture was homogenized for 15 min at 2000 rpm (rotation per 
minute), and sonicated for 10 min. By evaporation technique the 
organic solvents were removed at 40 °C (degree centigrade) under 
normal pressure, and the nanoparticles were separated by using 
cooling centrifuge for 15 min at 10000 rpm. Supernatant liquid was 
removed and nanoparticles were washed with distilled water and 
freeze dried using mannitol as cryoprotectant [14]. 
Preparation of SLN loaded transdermal film 
SLN loaded transdermal films were formulated by solvent casting 
method [15]. Polymers eudragit rs 100 (E. RS 100) and eudragit l 100 
(E. L 100) were dissolved in ethanol and water, respectively to which 
12 mg (milligram) rivastigmine tartrate SLN, plasticizer (glycerol 2-
4%) and small amount of film forming agent (HPMC) were added. The 
resultant dispersion was stirred using magnetic stirrer at 1000 rpm 
for 45 min. The dispersion was then transferred into a petridish placed 
on the even surface and was allowed to dry for 96 h in desicator with 
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nitrogen atmosphere. Circular films of 2 cm (centimeter) diameter 
(3.14 cm2) were cut from dried films and placed in desiccators at 
reduced pressure. The various formulations obtained by application of 
factorial design are presented in table 1 [16]. 
 
Table 1: Matrix of 23 factorial designs for SLN loaded film 
Formulation code Rivastigmine SLN (mg) Polymer (%) Plasticizer (%) 
(ERS 100) (EL 100) 
K1 Equivalent to 12 mg of drug 1.5 0.5 2 
K2 0.5 1.5 4 
K3 1.5 0.5 4 
K4 0.5 0.5 4 
K5 1.0 1.0 3 
K6 0.5 0.5 2 
K7 0.5 1.5 2 
K8 1.5 1.5 4 
K9 1.5 1.5 2 
mg: milligram, %: percentage, evaluation of rivastigmine tartrate SLN loaded transdermal films 
 
Thickness 
By using digital vernier calipers, the thickness of the films were 
measured at three different places, and mean value was calculated [17]. 
Weight variation 
Weight variation of films was performed by individually weighing 3 
randomly selected films and performed for each formulation and 
mean value was calculated [18]. 
Flatness 
Three longitudinal strips were cut out from each film: 1 each from 
the center, left side, and right side. The length of each strip was 
measured, and the variation in length because of non-uniformity in 
flatness was measured by determining percent constriction, with 





Where, L1 initial length of each strip, L2, final length. 
Folding endurance 
Folding endurance was determined by repeatedly folding the films 
at the same place until it broke. The number of times the film could 
be folded at the same place without breaking was the folding 
endurance value [19]. 
Drug content 
A prepared film was added to 100 ml saline phosphate buffer (pH 
6.8) and stirred vigorously for 24 h followed by ultra-sonication for 
15 min. The contents were filtered, and drug was estimated 
spectrophotometrically at wavelength of 263 nm [20, 21]. 
Water vapour transmission rate 
Glass vials of equal diameter were used as transmission cells. These 
transmission cells were washed thoroughly and dried in an oven. 
About 1 gm (gram) anhydrous calcium chloride was placed in the 
cells and the respective polymer films were fixed over the brim. The 
cells were accurately weighed and kept in a closed desiccators 
containing saturated solution of potassium chloride to maintain a 
humidity of 84%. The cells were taken out and weighed after 6, 12, 
24, 36, 48 and 72 h of storage to note down the weight gain [22]. 
Water vapour transmission rate =




Completely dried films with a required area were weighed and 
placed in desiccators for 24 h. the films were removed and exposed 
to relative humidity (RH) conditions of 75% (containing saturated 
solution of sodium chloride) in desiccators. Weight was taken on a 
single pan balance periodically until a constant weight was obtained. 
The capacity of the films swelling (in weight %) was calculated in 
terms of percentage increase in weight of membrane over the initial 
weight of the specimen. The experiments were conducted in 
triplicate and the average values were used for the calculation. The 





Where, Wd and Ws indicate the weight of the dry and swollen films 
respectively [23]. 
Tensile strength 
Mechanical properties of the films were evaluated using universal 
testing machine (Model 1121, Instron Ltd., Japan) with a 2-kilogram load 
cell. SLN film of known dimension was positioned between two clamps 
at a distance of 5 cm. The SLN film was pulled by the clamp at the rate of 
50 mm/min. Measurements were run in triplicate for each film.  
Tensile strength (N/mm2) is the maximum stress applied to a point 
at which the film breaks and can be computed from the applied force 
at rupture as a mean of three measurements and the cross-sectional 
area of the fractured film [24].  
Tensile strength =
Force at break (N)
Initial cross sectional area of the film (mm2)
 
In vitro drug release study 
The in vitro drug release study of SLN film was performed by using 
Franz diffusion type cell. The study was performed at 37±0.5 °C, 
Receptor compartment of diffusion cell contained 20 ml of 
phosphate buffer (pH-6.8) solution and was constantly stirred by a 
magnetic stirrer at 100 rpm. Cellophane membrane (molecular 
weight cut off 10,000-12,000, Hi-Media, India), was employed as 
release barrier in between receptor and donor compartment which 
was previously soaked in distilled water. Test samples were 
withdrawn on definite time intervals from sampling port of the 
diffusion cell and immediately replaced with an equal volume of 
fresh buffer. The amount of drug released was quantified using the 
high performance liquid chromatography (HPLC) method by directly 
injecting samples to the HPLC system at 263 nm [25, 26]. 
Ex vivo permeation study of SLN loaded transdermal films 
Animals were purchased from Biogen laboratory animal facility, Reg. 
No. 971/bc/06, Bill No. 1353. The skin samples of Newzealand white 
rabbit weighing 3 kg were continuously housed at the institution 
animal facility. Study was conducted after the approval from 
institutional animal’s ethics committee, JSS College of Pharmacy, 
Mysuru. (Proposal No. 215/2017).  
The skin sample was mounted carefully on franz-type diffusion type 
cell with the stratum corneum side up with an effective diffusion 
area of 2.0 cm2. The receiver compartments were filled with 20 ml of 
phosphate buffer (pH-6.8) solution to ensure sink condition. The 
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diffusion cells were maintained at 37±0.5 °C with stirring at 100 rpm 
during the experiment. 2.0 cm2 transdermal film of SLN was 
mounted onto surface of skin, from the medium 1 ml of the sample 
was withdrawn at definite time intervals (0, 0.5, 1, 2, 4, 6, 8, 10, 12, 
16, 20 and 24 h) and replaced same volume of fresh phosphate 
buffer. All the test samples were filtered through a whatman filter 
membrane and by using HPLC the samples were analysed [27-29]. 
RESULTS AND DISCUSSION 
Evaluation of SLN loaded transdermal film 
The transdermal film containing rivastigmine SLN were prepared 
and evaluated. The evaluation results were summarized in table 2. 
The thickness of transdermal films of ranged between (0.22±0.06 to 
0.39±0.02 mm). The weight variation range of 132.7±1.79 to 
141.4±2.45 mg indicated that different batches of prepared films 
had similar weights. The % flatness study showed 100% thus 
indicating a lack of constriction. Folding endurance results ranged 
between 66±3.19 and 78±4.38 indicating the capacity of films to 
maintain their integrity with general skin folding when applied. In a 
previous study the optimized formulation of film has shown 
thickness more (0.55 mm) and weight of the film 351.45 mg [30]. 
In vitro drug release 
The cumulative percentage of drug release from the transdermal 
film of different formulations is shown in fig. 1and 2. Rivastigmine 
tartrate transdermal films showed good in drug release. The 
percentage release was found to be highest is 96.1±0.48% at 24th h. 
In a previous study done by Nikhil B et al., the optimized formulation 
has shown cumulative drug release 95.70% at 24th h [31]. 
 















K1 0.25±0.02 135.3±1.18 100 68±3.36 98.46±0.5 4.78×10-4 31.74±0.82 
K2 0.35±0.08 138.6±1.45 100 72±3.68 97.62±0.1 5.36×10-4 40.52±0.42 
K3 0.39±0.02 132.7±1.79 100 66±4.57 98.18±0.7 4.64×10-4 39.76±0.81 
K4 0.31±0.01 134.3±1.52 100 74±3.24 97.69±0.3 4.82×10-4 38.56±0.77 
K5 0.29±0.09 139.2±1.63 100 69±4.71 97.78±0.9 4.66×10-4 42.47±0.25 
K6 0.38±0.06 138.9±1.38 100 75±3.29 98.51±0.2 3.93×10-4 39.85±0.58 
K7 0.37±0.01 136.5±2.02 100 72±4.45 98.69±0.7 5.73×10-4 38.41±0.75 
K8 0.22±0.06 139.4±1.76 100 78±4.38 98.97±0.5 4.68×10-4 41.48±0.18 
K9 0.28±0.08 141.4±2.45 100 66±3.19 98.81±0.3 5.17×10-4 37.34±0.89 
mg: milligram; cm: centimeter; mm: millimeter; %: percentage, *Average of three readings±SD 
 
 
Fig. 1: In vitro drug release profile of formulations (K1-K5) (n=3), n=3 average of three determinations 
 
 
Fig. 2: In vitro drug release profile of formulations (K6-K9) (n=3), n=3Average of three determinations 
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Ex Vivo skin permeation study 
The ex vivo skin permeation study release from the transdermal film 
of various formulations is shown in fig. 3 and 4. Rivastigmine 
tartrate transdermal films showed good in drug release. The 
percentage release was found to be highest is 97.36±0.93% at 24th h. 
In a previous study done by Nikhil B et al., the permeation study has 
shown 96.90±0.695% drug permeation at 24th h [31]. 
 
 
Fig. 3: Ex vivo skin permeation profile of formulations (K1-K5) (n=3), n=3 average of three determinations 
 
 
Fig. 4: Ex vivo skin permeation profile of formulations (K6-K9) (n=3), n=3Average of three determinations 
 
By conducting preliminary trials with relative ratio of the selected two 
components i.e. E. RS 100, E. L100 and plasticizer on the previous 
related experiences, the low and the higher limits of each variable 
were defined (table 3). To evaluate all the possible combination of 
excipients in the initial formulation system, a full factorial DoE was 
performed and the results obtained are shown in table 4. 
 
Table 3: Variables in 23factorial designs for SLN loaded transdermal film 
Independent variables Levels 
Low High 
A: Eudragit RS 100 (mg) 50 150 
B: Eudragit L 100 (mg) 50 150 
C: Plasticizer (%) 2 4 
Dependent variables, R1: Tensile strength (N/mm2), R2: Cumulative Drug release (%) 24th h 
 
Table 4: Observed response in 23 factorial design for SLN loaded transdermal film 
Formulation code Polymer (%) Plasticizer 
(%) 
Responses 
E. RS 100 E. L 100 Tensile strength* (N/mm2) Cumulative drug release (%) 24th h* 
K1 1.5 0.5 2 11.56±0.03 94.28±0.48 
K2 0.5 1.5 4 5.47±0.07 86.24±0.25 
K3 1.5 0.5 4 7.1±0.02 89.45±0.57 
K4 0.5 0.5 4 6.86±0.09 88.72±0.99 
K5 1.0 1.0 3 7.74±0.11 90.57±0.45 
K6 0.5 0.5 2 9.28±0.07 92.47±0.86 
K7 0.5 1.5 2 8.63±0.08 91.39±0.37 
K8 1.5 1.5 4 6.28±0.06 87.43±0.61 
K9 1.5 1.5 2 10.41±0.05 93.36±0.44 
 *mean±SD, n=3, the results depicts that variables chosen have strong influence on the selected responses, as tensile strength and percentage 
cumulative drug releasevalues were in the range of 5.47-11.56 N/mm2 and 86.24-94.28% respectively. 
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The application of factorial design yielded the following 
regression equations 
Tensile Strength (N/mm2) =+13.18653+0.012775 * E RS 100-
0.010025 * E L100-1.77125 * Plasticizer 
Cumulative drug release(%) =+95.04694+0.025100 * E RS 100-
6.00000E-004 * E L100-1.36750 * Plasticizer+3.10000E–005 * E RS 
100 * E L100-4.65000E–003 * E RS 100 * Plasticizer-6.25000E–003 
* EL100 * Plasticizer 
Where negative values indicate a negative effect of a specific variable on 
the response factor and positive value indicates positive effect of a 
specific variable. The polynomial regression results were expressed 
using Contour graphs, predicted and actual graphs and 3-D graphs. 
Tensile strength (N/mm2)  
The regression equation depcits, the effect of E. RS 100, E. L 100 and 
plasticizer on tensile strength, and the obtained result indicate a 
positive effect on tensile strength. Higher concentration of E. RS 100 
and lower concentration of E. L 100, plasticizer showed more tensile 
strength. The results presented in fig. 5 below. 
Cumulative drug release 
Results of regression analysis shows that, tensile strength was inversely 
proportional to the drug release i. e as the tensile strength of the films 
decreases, an increase in the drug release was observed. Higher 
concentration of E. RS 100 and lower concentration of E. L 100, 
plasticizer showed faster drug release. The results are presented in fig. 6. 
 
 
Fig. 5: Predicted V/S actual plot and cube plot depicting the impact of polymer and plasticizer on tensile Strength (N/mm2) respectively 
 
 
Fig. 6: Predicted V/S actual plot and cube plot depicting the impact of polymer and plasticizer on Cumulative drug release (%) respectively 
 
CONCLUSION 
In the present investigation we, concluded that the in vitro drug 
release as well as skin permeation profiles of rivastigmine tartrate 
solid lipid nanoparticles from transdermal systems were found to be 
greatly influenced by the formulation variables such as rivastigmine 
tartrate SLN loading, polymer and plasticizer concentration and 
these variables could be suitably altered to achieve the desired 
controlled release profile of rivastigmine tartrate. The design of 
experiment with response surface method is an efficient tool to 
determine and optimize formulation conditions within experimental 
conditions. Overall, an optimized rivastigmine tartrate SLN loaded 
transdermal film was successfully developed which could control 
the release as well as permeation of rivastigmine tartrate up to 24 h. 
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